Biocompatibles to return £100 million to shareholders
This article was originally published in Clinica
Executive Summary
Biocompatibles plans to give shareholders back around £100 million ($143 million) following criticism from analysts and investors about the company's planned sale of its coronary stent business to Abbott for $235 million (see Clinica No 1001, p 15). At the same time, the UK company has been named co-defendant in a lawsuit filed by US company Isostent.